Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcino...
Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma
About this item
Full title
Author / Creator
Kong, Fan-Hua , Ye, Qi-Fa , Miao, Xiong-Ying , Liu, Xi , Huang, Si-Qi , Xiong, Li , Wen, Yu and Zhang, Zi-Jian
Publisher
Australia: Ivyspring International Publisher Pty Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Australia: Ivyspring International Publisher Pty Ltd
Subjects
More information
Scope and Contents
Contents
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the leading causes of cancer-related death worldwide. Advanced HCC displays strong resistance to chemotherapy, and traditional chemotherapy drugs do not achieve satisfactory therapeutic efficacy. Sorafenib is an oral kinase inhibitor that inhibits tumor cell prolifera...
Alternative Titles
Full title
Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8039945
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8039945
Other Identifiers
ISSN
1838-7640
E-ISSN
1838-7640
DOI
10.7150/thno.54822
